Smart Money is Buying Baxter International Inc. (BAX)
Monday, April 20, 2026 · Johnny Hopkins
According to the most recent 13F filings, institutional investors showed broad-based buying interest in Baxter International Inc. (BAX), with activity spanning value-oriented managers, deep-value contrarians, and quantitative funds. This accumulation suggests growing confidence in Baxter’s recovery potential, turnaround efforts, and its defensive positioning within the healthcare sector. Below are the most notable buyers from the last quarter:
PZENA INVESTMENT MANAGEMENT LLC (Rich Pzena) Shares: 70,046,251 Change: +12,659,211 Value: $1.34B
Rich Pzena led activity with a massive increase, signaling strong conviction in Baxter as a classic value play. This move likely reflects a belief that the stock is undervalued relative to its long-term earnings power and restructuring goals.
GREENHAVEN ASSOCIATES INC (Ed Wachenheim) Shares: 10,693,223 Change: +4,404,874 Value: $0.20B
Ed Wachenheim significantly expanded his stake, reinforcing Baxter as a core position. Greenhaven’s style typically favors high-quality companies facing temporary headwinds, suggesting they see a clear path to price appreciation.
AQR CAPITAL MANAGEMENT LLC (Cliff Asness) Shares: 603,295 Change: +315,353 Value: $0.01B
AQR more than doubled its position, likely supported by quantitative factors such as value metrics and stabilizing earnings revisions within the medical technology space.
OLSTEIN CAPITAL MANAGEMENT, L.P. (Rob Olstein) Shares: 417,000 Change: +52,000 Value: $0.00B
Rob Olstein added to the position, consistent with a “look-at-the-ball” fundamental approach that prioritizes free cash flow and conservative accounting over market sentiment.
GAMCO INVESTORS, INC. ET AL (Mario Gabelli) Shares: 391,250 Change: +35,300 Value: $0.01B
Mario Gabelli’s firm modestly increased its exposure, likely identifying Baxter as a potential catalyst-driven play amidst ongoing corporate streamlining and spin-off activity.
BRIDGEWATER ASSOCIATES, LP (Ray Dalio) Shares: 210,800 Change: +30,290 Value: $0.00B
Bridgewater increased its stake, consistent with macro exposure to defensive healthcare sectors and stabilizing global medical supply chains.
FISHER ASSET MANAGEMENT, LLC (Ken Fisher) Shares: 13,571 Change: NEW POSITION Value: $0.00B
Ken Fisher established a new position this quarter. While small, the initiation of a stake suggests Baxter has re-entered the radar of large-scale growth and income managers.
Overall Takeaway
Collectively, these filings highlight significant institutional accumulation of Baxter shares, dominated by a massive 12.6 million share addition from Pzena Investment Management and a major increase from Greenhaven Associates.
The concentration of buyers among prominent value and contrarian investors suggests a broad conviction that BAX is a “turnaround” story. As Baxter continues to navigate its operational restructuring and debt reduction, it appears well-positioned to attract capital from investors seeking undervalued healthcare assets with durable cash flow and essential product portfolios.